Drug intelligence / Profile preview

methotrexate + docetaxel + oxaliplatin

Development stage: Unknown
Lead developer: medac
Modality: Small Molecules
Administration: Intravenous

Overview

Medoxa is a combination chemotherapy regimen comprising methotrexate, docetaxel, and oxaliplatin, investigated by the Frankfurter Institut für Klinische Krebsforschung (IKF) for the treatment of advanced or metastatic adenocarcinoma of the esophagus and gastroesophageal junction. The regimen combines three distinct mechanisms of action: methotrexate acts as an antimetabolite by inhibiting dihydrofolate reductase, docetaxel functions as a taxane that promotes microtubule assembly and inhibits disassembly, and oxaliplatin is a platinum derivative that induces DNA damage through the formation of intra- and interstrand cross-links. This combination aims to improve response rates and survival in patients with upper gastrointestinal malignancies.

Brand names: Medoxa
Other names: MTX/DOC/OXA

Targets

DNADHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on methotrexate + docetaxel + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + docetaxel + oxaliplatin.

Explore the full profile